Loading
A phase 3 trial of aumolertinib in lung cancer, run by Guangdong Association of Clinical Trials, active but no longer recruiting.
MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) is a phase 3, randomised interventional study registered as NCT04841811 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 192 participants, started 2022-06-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: Almonertinib. Conditions listed: Lung Cancer. Primary outcome: Assess the anti-tumor activity by IRC: ORR; Assess the anti-tumor activity by IRC: Event free survival (EFS) rate. Lung eligibility wording from the registry: "Stage III non-squamous cell non-small cell lung cancer confirmed by histopathology or cytology and determined by the investigator to be unresectable (International Association for the Study of Lung Cancer Eighth Edition Lung Cancer Staging)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.